Injectable antibody drug protects children from malaria in Mali trial
A single dose of an experimental antibody drug protects children from malaria for up to 6 months, according to a clinical study published today in
The New England Journal of Medicine
.
The therapy, an injectable monoclonal antibody called L9LS that has
already shown success in adults
, reduced infections and clinical disease in 6- to 10-year-olds in Mali. Although the drug is still undergoing clinical testing, the results suggest monoclonal antibodies could be an important addition to the arsenal against this deadly disease, researchers say.
Malaria caused an estimated 608,000 deaths in 2022...
Source: ScienceNOW - April 26, 2024 Category: Science Source Type: news
Africa: TB Clinical Trials: An UnPrecedented €34 Million Price Tag in Drug Development
[MSF] Geneva -- At the 5th WHO Pharmaceutical Pricing and Reimbursement Policies conference today, Doctors Without Borders (MSF) presented the costs of its landmark TB-PRACTECAL clinical trial that helped identify a shorter, all-oral treatment regimen for drug-resistant tuberculosis (DR-TB),* which totalled €34 million. This is the first time the detailed costs of an individual clinical trial will have ever been shared publicly, challenging the lack of transparency around drug development and the prevailing public (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 26, 2024 Category: African Health Tags: Africa Health and Medicine Tuberculosis Source Type: news
Prominent ALS Researcher Moves From Treatment to Prevention Prominent ALS Researcher Moves From Treatment to Prevention
After years of disappointing ALS clinical trial results, this year ' s Sheila Essey Award recipient for significant contributions in ALS research is shifting to prevention.MDedge News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 26, 2024 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Investigating cognitive and motivational proximal outcomes in a randomized clinical trial of writing about the future self to reduce drinking - Lindgren KP, Baldwin SA, Kross E, Ramirez JJ, Tristao T, Peterson KP, Teachman BA, Wiers RW, Neighbors C.
BACKGROUND: Drinking identity (the extent to which one links the self with drinking alcohol) is a unique risk factor for college students' hazardous drinking that is not directly targeted by existing interventions. We conducted a study that aimed to decrea... (Source: SafetyLit)
Source: SafetyLit - April 26, 2024 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
State of the science: prolonged exposure therapy for the treatment of posttraumatic stress disorder - McLean CP, Foa EB.
Prolonged exposure therapy (PE) is a well-established first-line treatment for posttraumatic stress disorder (PTSD) that is based on emotional processing theory. PE has been rigorously evaluated and tested in a large number of clinical trials in many count... (Source: SafetyLit)
Source: SafetyLit - April 25, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
Impact of repeated preheating of bulk-fill resin composite on postoperative hypersensitivity; a randomized controlled clinical trial
ConclusionThe
repeated preheating cycles of bulk-fill resin composite prior to curing
had no adverse effect on the patients regarding postoperative dentin
hypersensitivity. This information could be of utmost significance, as
the same resin composite syringe can undergo numerous preheating cycles
clinically before it is completely consumed with the advantage of
improvement on the handling properties. (Source: Dental Technology Blog)
Source: Dental Technology Blog - April 25, 2024 Category: Dentistry Source Type: news
Introducing Citeline PatientMatch for Precision Patient Recruitment
Introducing Citeline PatientMatch, delivering custom-timed alerts when patients receive lab or biomarker results that could make them eligible for a clinical trial. NEW YORK, April 25, 2024 /PRNewswire-PRWeb/ -- Due to more complex protocol designs, stricter inclusion/exclusion criteria... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 25, 2024 Category: Pharmaceuticals Source Type: news
Strategies for Global Clinical Trials: Clinical Research Without Borders, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn about the importance of cross-border enrollment in global clinical trials, including its influence on participant diversity and trial completion speed. Attendees will learn key strategies for navigating global regulations, logistical support and operational... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 25, 2024 Category: Pharmaceuticals Tags: FVT TRI Source Type: news
Importance of Pre-Planning for Successful Clinical Trials, Upcoming Webinar Hosted by Xtalks
In this free webinar, which is part of a series addressing key challenges facing clinical trial sponsors, attendees will gain insights into the importance of pre-planning for successful clinical trials. Hear about a pre-planning model that can mitigate some of the challenges in clinical... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 25, 2024 Category: Pharmaceuticals Tags: TRI FVT Source Type: news
What's Going On With Palantir Technologies Today?
Palantir Technologies Inc. PLTR shares are trading lower in the premarket session on Thursday. The AI giant inked a multi-year strategic partnership with clinical research organization Parexel to enhance and accelerate the delivery of safe and effective clinical trials for the world’s…#pltr #parexel #cronos #jonathanshough #palantirfoundry #lalarukhharisshaikh #palantir (Source: Reuters: Health)
Source: Reuters: Health - April 25, 2024 Category: Consumer Health News Source Type: news
Today ’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
ILAG and FBL are leading our lists this morning Pre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning! Moving stocks this morning are earnings reports, clinical trial data, a delisting notice and more. Let’s get into that news…#ilag #fbl #intelligentliving #realphatech #cidaratherapeutics #cdtx #nutexhealth #nutx #acrivontherapeutics #hwhinternational (Source: Reuters: Health)
Source: Reuters: Health - April 25, 2024 Category: Consumer Health News Source Type: news
Hookipa Pharma Announces Major HB-200 Clinical Trial Design
https://www.tipranks.com/news/company-announcements/hookipa-pharma-announces-major-hb-200-clinical-trial-design?utm_source=biztoc.com&utm_medium=referral (Source: Reuters: Health)
Source: Reuters: Health - April 25, 2024 Category: Consumer Health News Source Type: news
Median posts Q1 results, reports net loss for 2023
France-based Median Technologies recently posted financial results for the first quarter of the 2024 fiscal year, which ended March 31.
The company reported that revenue for the quarter was 5.4 million euros ($5.8 million), comparable to the same quarter in 2023. Median's revenue is achieved entirely by the iCRO1 business, which delivers services to the global biopharmaceutical industry for image management in oncology clinical trials.
Median said that first-quarter revenues were affected by the postponement of some studies to the second quarter of 2024 due to late patient recruitment.
Additionally, the company reported...
Source: AuntMinnie.com Headlines - April 25, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Portland biotech Sparrow Pharmaceuticals raises $10M to further clinical trials
Sparrow Pharmaceuticals is developing, novel targeted therapies for disorders caused by excess corticosteroids. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 24, 2024 Category: Pharmaceuticals Authors: Elizabeth Hayes Source Type: news
CBT Beats Mindfulness for Prolonged Grief Disorder
(MedPage Today) -- Cognitive behavior therapy (CBT) bested mindfulness therapy for patients with prolonged grief disorder, a randomized clinical trial showed.
In Australian study of 100 patients, grief-focused CBT led to greater reductions in... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - April 24, 2024 Category: Psychiatry Source Type: news
